ETRA
Electra Therapeutics, Inc.
Price Chart
Latest Quote
$8.52
+0.15 (+1.79%)
Current Price
| Previous Close | $8.37 |
| Open | $8.37 |
| Day High | $8.88 |
| Day Low | $8.32 |
| Volume | 176,272 |
Stock Information
| Shares Outstanding | 62.77M |
| Total Debt | $1.98M |
| Cash Equivalents | $97.72M |
| Net Income | $-95.20M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $534.77M |
| EPS (TTM) | $-2.65 |
| Exchange | NMS |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $736.00M |
| Income | $-95.20M |
| Book/sh | $-4987.61 |
| Cash/sh | $1.56 |
| Employees | 46 |
Financial Ratios
| Quick Ratio | 7.19 |
| Current Ratio | 7.37 |
| Debt/Eq | 2.16 |
Returns & Margins
Ownership
| Insider Ownership | 1.37% |
| Institutional Ownership | 27.84% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | -4.74 |
| P/B | -0.00 |
Analyst Data
| Recommendation | strong_buy |
| Target Price | $33.20 |
Technical Indicators
| SMA20 | $9.24 |
| RSI | 40.70 |
| ATR | 0.7250 |
| Shares Float | 29.12M |
| Short Ratio | 0.61 |
| Rel Volume | 0.38 |
Performance History
| Week | -3.29% |
| Month | -24.73% |
| YTD | -35.70% |
| 10 Years | -35.70% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-10-27 | $8.52 | 176,800 |
| 2026-10-26 | $8.37 | 159,100 |
| 2026-10-23 | $8.71 | 186,500 |
| 2026-10-22 | $9.25 | 155,800 |
| 2026-10-21 | $9.05 | 126,100 |
| 2026-10-20 | $8.81 | 177,700 |
| 2026-10-19 | $8.61 | 309,000 |
| 2026-10-16 | $8.75 | 1,380,500 |
| 2026-10-15 | $8.75 | 179,600 |
| 2026-10-14 | $8.94 | 521,000 |
| 2026-10-13 | $8.61 | 552,300 |
| 2026-10-12 | $9.32 | 346,700 |
| 2026-10-09 | $9.04 | 778,500 |
| 2026-10-08 | $9.14 | 408,000 |
| 2026-10-07 | $9.16 | 407,300 |
| 2026-10-06 | $9.82 | 276,200 |
| 2026-10-05 | $9.74 | 334,400 |
| 2026-10-02 | $10.37 | 696,600 |
| 2026-10-01 | $10.68 | 1,255,400 |
| 2026-09-30 | $11.25 | 925,700 |
| 2026-09-29 | $11.35 | 715,600 |
| 2026-09-28 | $11.32 | 537,100 |
About Electra Therapeutics, Inc.
Electra Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The company develops therapies that targets signal regulatory proteins for the treatment of novel targets for treatment of immune-mediated diseases and cancer. Its lead product candidate is ipsoprubart, that targets signal regulatory protein on the cell surface of myeloid and T cells and depletes pathological immune cells, treatment for secondary hemophagocytic lymphohistiocytosis and T/NK Cell Malignancies; ELA822, a novel SIRP-specific monoclonal antibody for deplete activated T cells, treatment for T cell mediated immune disorders. Electra Therapeutics, Inc. was incorporated in 2018 and is based in South San Francisco, California.
đ° Latest News
No news articles available at the moment. Check back later for updates on ETRA.
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Revenue | ||
| Total Revenue | $0 | $0 |
| Operating Revenue | $0 | $0 |
| Expenses | ||
| Interest Expense | $1,433,000 | $0 |
| Total Expenses | $61,889,000 | $26,317,000 |
| Other Income Expense | $-15,000 | $7,000 |
| Other Non Operating Income Expenses | $-15,000 | $7,000 |
| Net Non Operating Interest Income Expense | $-71,000 | $1,524,000 |
| Interest Expense Non Operating | $1,433,000 | $0 |
| Operating Expense | $61,889,000 | $26,317,000 |
| General And Administrative Expense | $11,502,000 | $7,050,000 |
| Income & Earnings | ||
| Net Income From Continuing Operation Net Minority Interest | $-61,975,000 | $-24,786,000 |
| Net Interest Income | $-71,000 | $1,524,000 |
| Interest Income | $1,362,000 | $1,524,000 |
| Normalized Income | $-61,975,000 | $-24,786,000 |
| Net Income From Continuing And Discontinued Operation | $-61,975,000 | $-24,786,000 |
| Total Operating Income As Reported | $-61,889,000 | $-26,317,000 |
| Net Income Common Stockholders | $-61,975,000 | $-24,786,000 |
| Net Income | $-61,975,000 | $-24,786,000 |
| Net Income Including Noncontrolling Interests | $-61,975,000 | $-24,786,000 |
| Net Income Continuous Operations | $-61,975,000 | $-24,786,000 |
| Pretax Income | $-61,975,000 | $-24,786,000 |
| Interest Income Non Operating | $1,362,000 | $1,524,000 |
| Operating Income | $-61,889,000 | $-26,317,000 |
| Per Share | ||
| Diluted EPS | $-1.80 | $-0.63 |
| Basic EPS | $-1.80 | $-0.63 |
| Other | ||
| Tax Effect Of Unusual Items | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-60,481,000 | $-24,786,000 |
| Reconciled Depreciation | $61,000 | $0 |
| EBITDA (Bullshit earnings) | $-60,481,000 | $-24,786,000 |
| EBIT | $-60,542,000 | $-24,786,000 |
| Diluted Average Shares | $34,515,144 | $39,433,621 |
| Basic Average Shares | $34,515,144 | $39,433,621 |
| Diluted NI Availto Com Stockholders | $-61,975,000 | $-24,786,000 |
| Research And Development | $50,387,000 | $19,267,000 |
| Selling General And Administration | $11,502,000 | $7,050,000 |
| Other Gand A | $8,132,000 | $4,216,000 |
| Salaries And Wages | $3,370,000 | $2,834,000 |
Fetched: 2026-10-24
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Assets | ||
| Net Tangible Assets | $-30,326,000 | $-103,261,000 |
| Total Assets | $99,368,000 | $19,420,000 |
| Total Non Current Assets | $3,882,000 | $0 |
| Other Non Current Assets | $1,098,000 | - |
| Current Assets | $95,486,000 | $19,420,000 |
| Other Current Assets | $179,000 | $165,000 |
| Prepaid Assets | $8,569,000 | $3,415,000 |
| Receivables | $220,000 | $55,000 |
| Other Receivables | $220,000 | $55,000 |
| Cash Cash Equivalents And Short Term Investments | $86,518,000 | $15,785,000 |
| Cash And Cash Equivalents | $33,008,000 | $14,787,000 |
| Debt | ||
| Total Debt | $2,087,000 | $0 |
| Long Term Debt And Capital Lease Obligation | $1,482,000 | $0 |
| Current Debt And Capital Lease Obligation | $605,000 | - |
| Liabilities | ||
| Total Liabilities Net Minority Interest | $129,694,000 | $122,681,000 |
| Total Non Current Liabilities Net Minority Interest | $119,968,000 | $118,486,000 |
| Current Liabilities | $9,726,000 | $4,195,000 |
| Payables And Accrued Expenses | $7,107,000 | $2,936,000 |
| Payables | $4,076,000 | $1,535,000 |
| Accounts Payable | $4,076,000 | $1,535,000 |
| Equity | ||
| Common Stock Equity | $-163,442,000 | $-103,261,000 |
| Preferred Stock Equity | $133,116,000 | - |
| Total Equity Gross Minority Interest | $-30,326,000 | $-103,261,000 |
| Stockholders Equity | $-30,326,000 | $-103,261,000 |
| Gains Losses Not Affecting Retained Earnings | $21,000 | $1,000 |
| Other Equity Adjustments | $21,000 | $1,000 |
| Retained Earnings | $-172,978,000 | $-111,003,000 |
| Preferred Securities Outside Stock Equity | $118,486,000 | $118,486,000 |
| Other | ||
| Ordinary Shares Number | $62,766,955 | $62,766,955 |
| Share Issued | $62,766,955 | $62,766,955 |
| Tangible Book Value | $-163,442,000 | $-103,261,000 |
| Invested Capital | $-163,442,000 | $-103,261,000 |
| Working Capital | $85,760,000 | $15,225,000 |
| Capital Lease Obligations | $2,087,000 | $0 |
| Total Capitalization | $-30,326,000 | $-103,261,000 |
| Additional Paid In Capital | $9,515,000 | $7,741,000 |
| Capital Stock | $133,116,000 | $0 |
| Common Stock | $0 | $0 |
| Preferred Stock | $133,116,000 | $0 |
| Long Term Capital Lease Obligation | $1,482,000 | $0 |
| Current Capital Lease Obligation | $605,000 | $0 |
| Pensionand Other Post Retirement Benefit Plans Current | $2,014,000 | $1,259,000 |
| Current Accrued Expenses | $3,031,000 | $1,401,000 |
| Net PPE | $2,784,000 | $0 |
| Gross PPE | $2,784,000 | $0 |
| Other Properties | $2,784,000 | - |
| Other Short Term Investments | $53,510,000 | $998,000 |
Fetched: 2026-10-24
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Free Cash Flow | ||
| Free Cash Flow | $-61,217,000 | $-26,003,000 |
| Operating Activities | ||
| Operating Cash Flow | $-60,484,000 | $-26,003,000 |
| Cash Flow From Continuing Operating Activities | $-60,484,000 | $-26,003,000 |
| Investing Activities | ||
| Capital Expenditure | $-733,000 | - |
| Investing Cash Flow | $-52,978,000 | $29,701,000 |
| Cash Flow From Continuing Investing Activities | $-52,978,000 | $29,701,000 |
| Financing Activities | ||
| Issuance Of Capital Stock | $91,683,000 | $0 |
| Financing Cash Flow | $131,683,000 | $0 |
| Cash Flow From Continuing Financing Activities | $131,683,000 | $0 |
| Net Preferred Stock Issuance | $91,683,000 | $0 |
| Preferred Stock Issuance | $91,683,000 | $0 |
| Other | ||
| Issuance Of Debt | $40,000,000 | $0 |
| Income Tax Paid Supplemental Data | $8,000 | $27,000 |
| End Cash Position | $33,008,000 | $14,787,000 |
| Beginning Cash Position | $14,787,000 | $11,089,000 |
| Changes In Cash | $18,221,000 | $3,698,000 |
| Net Issuance Payments Of Debt | $40,000,000 | $0 |
| Net Long Term Debt Issuance | $40,000,000 | $0 |
| Long Term Debt Issuance | $40,000,000 | $0 |
| Net Investment Purchase And Sale | $-52,245,000 | $29,701,000 |
| Sale Of Investment | $1,000,000 | $34,500,000 |
| Purchase Of Investment | $-53,245,000 | $-4,799,000 |
| Net PPE Purchase And Sale | $-733,000 | $0 |
| Purchase Of PPE | $-733,000 | $0 |
| Change In Working Capital | $-1,744,000 | $-2,804,000 |
| Change In Other Current Liabilities | $-239,000 | $0 |
| Change In Other Current Assets | $-1,098,000 | $0 |
| Change In Payables And Accrued Expense | $4,926,000 | $417,000 |
| Change In Accrued Expense | $2,385,000 | $319,000 |
| Change In Payable | $2,541,000 | $98,000 |
| Change In Account Payable | $2,541,000 | $98,000 |
| Change In Prepaid Assets | $-5,168,000 | $-3,259,000 |
| Change In Receivables | $-165,000 | $38,000 |
| Other Non Cash Items | $1,648,000 | $-722,000 |
| Stock Based Compensation | $1,774,000 | $2,309,000 |
| Amortization Of Securities | $-248,000 | $-722,000 |
| Depreciation Amortization Depletion | $61,000 | $0 |
| Depreciation And Amortization | $61,000 | $0 |
| Net Income From Continuing Operations | $-61,975,000 | $-24,786,000 |
Fetched: 2026-10-24